Nivolumab (Opdivo®) for head and neck cancer

Assessment Status Rapid Review Complete
Drug Nivolumab
Brand Opdivo®
Indication For the treatment of squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.
Assessment Process
Rapid review commissioned 03/05/2017
Rapid review completed 30/05/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.

The HSE has approved reimbursement following confidential price negotiations May 2018.